For the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Axicabtagene ciloleucel is not indicated for the treatment of patients with primary central nervous system lymphoma.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/CHteOZl
No comments:
Post a Comment